Stay updated on Ponatinib for Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Ponatinib for Medullary Thyroid Cancer Clinical Trial page
- Check7 days agoChange DetectedThe record now presents details for the ponatinib study in advanced or metastatic medullary thyroid cancer, including its design, participant criteria, and outcome measures. It indicates the study was withdrawn by the sponsor and had actual enrollment of zero.SummaryDifference42%

- Check14 days agoChange DetectedThe displayed ClinicalTrials.gov site revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide notice announces NIH website updates and explains that some content may use “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check28 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 while the study page continues to display a 403 error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record content with an access-denied message. This indicates an accessibility issue rather than a substantive content update, leaving the page in an error state.SummaryDifference17%

Stay in the know with updates to Ponatinib for Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.